Tech Company Financing Transactions

CoLucid Pharmaceuticals Funding Round

CoLucid Pharmaceuticals closed a $37.1 million Series C funding round on 1/13/2015. Investors included TVM Capital, Auriga Partners and Care Capital.

Transaction Overview

Company Name
CoLucid Pharmaceuticals
Announced On
1/13/2015
Transaction Type
Venture Equity
Amount
$37,100,000
Round
Series C
Investors

TVM Capital (Lead Investor) (Luc Marengere)

Auriga Partners

Care Capital (Richard Markham)

Domain Associates (Jesse Treu)

Novo Ventures (Martin Edwards)

Pearl Street Ventures

Triathlon Medical Ventures

Proceeds Purpose
Proceeds from the Series C will be used to fund the Company's Phase 3 program for oral Lasmiditan, to include the first pivotal study, COL MIG-301 SAMURAI, for the acute treatment of migraine.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
P.O. Box 425227
Cambridge, MA 02142
USA
Phone
(781) 365-2596
Website
www.colucid.com
Email Address
[email protected]
Overview
CoLucid Pharma is a biotech company focusing on therapies for CNS disorders, Migraine, sleep/wake disorders, chronic pain, Alzheimers, and psychiatric disorders.
Profile
CoLucid Pharmaceuticals LinkedIn Company Profile
Social Media
CoLucid Pharmaceuticals Company Twitter Account
Company News
CoLucid Pharmaceuticals News
Facebook
CoLucid Pharmaceuticals on Facebook
YouTube
CoLucid Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Thomas Mathers
  Thomas Mathers LinkedIn Profile  Thomas Mathers Twitter Account  Thomas Mathers News  Thomas Mathers on Facebook
Chief Financial Officer
Matthew Dallas
  Matthew Dallas LinkedIn Profile  Matthew Dallas Twitter Account  Matthew Dallas News  Matthew Dallas on Facebook
VP - Bus. Development
Linda Hogan
  Linda Hogan LinkedIn Profile  Linda Hogan Twitter Account  Linda Hogan News  Linda Hogan on Facebook
VP - General Counsel
Daniel Boeglin
  Daniel Boeglin LinkedIn Profile  Daniel Boeglin Twitter Account  Daniel Boeglin News  Daniel Boeglin on Facebook
VP - R & D
Nadia Rupniak
  Nadia Rupniak LinkedIn Profile  Nadia Rupniak Twitter Account  Nadia Rupniak News  Nadia Rupniak on Facebook
VP - Regulatory Affairs
Bernice Kuca
  Bernice Kuca LinkedIn Profile  Bernice Kuca Twitter Account  Bernice Kuca News  Bernice Kuca on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/13/2015: True Fit venture capital transaction
Next: 1/14/2015: VelociData venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on every notable VC transaction. All VC database entries reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.